Peregrine Capital Management LLC Boosts Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Peregrine Capital Management LLC boosted its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 12.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 342,845 shares of the company’s stock after purchasing an additional 36,958 shares during the quarter. Peregrine Capital Management LLC owned about 0.38% of Myriad Genetics worth $4,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of MYGN. Loomis Sayles & Co. L P lifted its stake in Myriad Genetics by 153.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock worth $59,973,000 after purchasing an additional 1,326,497 shares in the last quarter. Disciplined Growth Investors Inc. MN raised its position in shares of Myriad Genetics by 21.1% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after buying an additional 440,107 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in shares of Myriad Genetics during the 3rd quarter valued at $11,007,000. State Street Corp raised its position in shares of Myriad Genetics by 8.3% during the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after buying an additional 359,685 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of Myriad Genetics by 26.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,063,711 shares of the company’s stock valued at $29,135,000 after buying an additional 224,255 shares in the last quarter. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on MYGN shares. Piper Sandler lowered their price objective on shares of Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, January 30th. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Craig Hallum began coverage on shares of Myriad Genetics in a research report on Wednesday, February 12th. They issued a “buy” rating and a $29.00 target price on the stock. The Goldman Sachs Group decreased their target price on shares of Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, Leerink Partnrs cut shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Myriad Genetics has a consensus rating of “Hold” and a consensus price target of $22.54.

Myriad Genetics Price Performance

Shares of Myriad Genetics stock opened at $14.90 on Thursday. The firm has a market cap of $1.36 billion, a PE ratio of -11.46 and a beta of 1.88. Myriad Genetics, Inc. has a 12-month low of $12.04 and a 12-month high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $13.45 and its two-hundred day simple moving average is $19.69.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.